GSK reported an in line top-line performance in its Q3 results. All revenue growth numbers at CER unless specified otherwise. Sales grew by 2% at CER to £7.8bn, with pharma (+2%) delivering better-than-expected results, courtesy of HIV and some established drugs, but both vaccine (flat) and consumer health (+2%) underperforming vs our estimates. Currency tailwinds added 2ppts to the CER growth. The US registered growth of 4% (+8% reported) and International of 1% (+2% reported), while E
31 Oct 2017
Results fine but market panics on dividend-funded shopping fears
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Results fine but market panics on dividend-funded shopping fears
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
31 Oct 2017 -
Author:
Kamla Singh -
Pages:
4
GSK reported an in line top-line performance in its Q3 results. All revenue growth numbers at CER unless specified otherwise. Sales grew by 2% at CER to £7.8bn, with pharma (+2%) delivering better-than-expected results, courtesy of HIV and some established drugs, but both vaccine (flat) and consumer health (+2%) underperforming vs our estimates. Currency tailwinds added 2ppts to the CER growth. The US registered growth of 4% (+8% reported) and International of 1% (+2% reported), while E